PMEF
FULC icon

Point72 Middle East FZE’s Fulcrum Therapeutics FULC Stock Holding History

Point72 Middle East FZE’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,145
Closed -$106K – 1595
2023
Q2 		$106K Buy
32,145
+27,834
+646% +$81.8K ﹤0.01% 1200
2023
Q1 		$12.3K Buy
+4,311
New +$38.6K ﹤0.01% 1472

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Point72 Middle East FZE's FULC Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Fulcrum Therapeutics (FULC) in Q3 2023, closing a stake of 32,145 shares — an estimated $106K sold.

Point72 Middle East FZE first reported a position in FULC in Q1 2023 and held it in 2 quarters. The position peaked at $106K in Q2 2023. 81 funds tracked by Wall St. Rank hold FULC as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Fulcrum Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 32,145 Fulcrum Therapeutics shares in Q3 2023, an estimated $106K.
  • Point72 Middle East FZE first reported a position in Fulcrum Therapeutics in Q1 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Fulcrum Therapeutics position peaked at $106K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.